Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in the Prognosis of Gastrointestinal Cancers
share announcement

Advances in the Prognosis of Gastrointestinal Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1446

Special Issue Editors

Dr. Chuanpeng Dong

E-Mail Website
Guest Editor
Department of Genetics, Yale University, New Haven, CT 06510, USA
Interests: multi-omics genome analysis; translational bioinformatics; cancer immunotherapy
Dr. Gang Liu

E-Mail Website
Guest Editor
Institute of Biomedical Sciences, Fudan University, Shanghai 200433, China
Interests: cancer classification; algorithm development; biomarker screening

Special Issue Information

Dear Colleagues,

Gastrointestinal cancers including pancreatic, colorectal, stomach and liver cancer are among the leading causes of cancer-related death globally with low survival rates. Gastrointestinal cancers account for approximately 15% of all cancer deaths worldwide. For decades, researchers and clinicians have reported numerous biomarkers to assess malignancy and predict outcomes. Currently, studies on the gastrointestinal cancer prognosis have mainly focused on identifying the meta-predictor, biomarkers at the genetic level, or the integration of both, and can be further categorized into different forms such as gene/epigenetic-profile-derived markers, invasive cell-free molecular biomarkers, etc. Along with rapidly developed sequencing technology and statistical, computational methods, there is still a strong need for leveraging new strategies for predicting pathological alterations and their association with the prognosis of gastrointestinal cancers.

This Special Issue aims to present original research and reviews on experimental and computational methods studying multi-omics and the contributions of phenotype data to the identification of novel biomarkers associated with gastrointestinal cancers, with a focus on cancer prognosis. We invite studies that investigate molecular signatures and gastrointestinal cancers using multi-omics sequencing techniques, including genomic and transcriptomic analysis, pathological images, and dedicated meta-analysis. We encourage research to identify potential biomarkers for the prognosis of gastrointestinal cancers, benefit of immunotherapy such as checkpoint and CAR-T therapies, and other critical outcome indicators. Please note that original research involving both in silico and experimental techniques are preferred.

Dr. Chuanpeng Dong
Dr. Gang Liu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal cancers
  • prognosis
  • prediction
  • immunotherapy
  • cancer prognosis

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 1049 KiB  
Article
Preoperative High C-Reactive Protein to Albumin Ratio Predicts Short- and Long-Term Postoperative Outcomes in Elderly Gastric Cancer Patients
by Yuki Takemoto, Kazuaki Tanabe, Emi Chikuie, Yoshihiro Saeki, Hiroshi Ota, Nozomi Karakuchi, Akihiro Kohata and Hideki Ohdan
Cancers 2024, 16(3), 616; https://doi.org/10.3390/cancers16030616 - 31 Jan 2024
Viewed by 739
Abstract
Individualized preoperative assessment of the general condition of elderly patients with gastric cancer is necessary for appropriate surgical treatment planning. This study investigated the efficacy of preoperative markers that could be easily calculated from preoperative peripheral blood to predict the short- and long-term [...] Read more.
Individualized preoperative assessment of the general condition of elderly patients with gastric cancer is necessary for appropriate surgical treatment planning. This study investigated the efficacy of preoperative markers that could be easily calculated from preoperative peripheral blood to predict the short- and long-term postoperative outcomes of gastrectomy. In total, 571 patients who underwent R0 surgical resection for gastric cancer were enrolled. In the elderly patient group (≥65 years old), univariate analyses revealed that the incidence of postoperative complications was associated with poor performance status (p = 0.012), more comorbidities (p = 0.020), high C-reactive protein to albumin ratio (CAR, p = 0.003), total gastrectomy (p = 0.003), open approach (p = 0.034), blood transfusion (p = 0.002), and advanced cancer (p = 0.003). Multivariate analysis showed that a high CAR was associated with a high incidence of postoperative complications (p = 0.046). High CAR was also associated with poor OS (p = 0.015) and RFS (p = 0.035). However, these trends were not observed among younger patients (<65 years old). Preoperative CAR may play a significant role in predicting short- and long-term surgical outcomes, particularly in elderly patients with gastric cancer. Full article
(This article belongs to the Special Issue Advances in the Prognosis of Gastrointestinal Cancers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 283 KiB  
Review
Prognosis and Treatment of Gastric Cancer: A 2024 Update
by Claudia Burz, Vlad Pop, Ciprian Silaghi, Iulia Lupan and Gabriel Samasca
Cancers 2024, 16(9), 1708; https://doi.org/10.3390/cancers16091708 - 27 Apr 2024
Viewed by 482
Abstract
Due to the high death rate associated with gastric cancer, a great deal of research has been conducted on this disease. The goal of this paper was to start a trimestral review of 2024 for the year that had just started. The scientific [...] Read more.
Due to the high death rate associated with gastric cancer, a great deal of research has been conducted on this disease. The goal of this paper was to start a trimestral review of 2024 for the year that had just started. The scientific literature from 1 January 2024 was chosen with consideration of the the guidelines of the European Society of Medical Oncology (ESMO), which are updated with new findings but not systematically reviewed annually. We used the search term “gastric cancer” to find the most current publications in the PubMed database related to the prognosis and treatment of gastric cancer. As previously said, the only articles that satisfied the inclusion criteria were those from 2024. Articles with case reports were eliminated since they had nothing to do with our research. The treatment of gastric cancer is the focus of the majority of articles from 2024. The primary research axes include surgery and immunonutrition, immunotherapy and Helicobacter pylori, and therapeutic targets. Patients with GC may experience less psychological, social, and financial hardship if the recently identified markers discovered in circulation are better assessed and validated. This could be achieved by either including the markers in an artificial intelligence-based diagnostic score or by using them in conjunction with traditional diagnostic methods. Due to the rising death rate associated with GC, funding for research into diagnosis, prognosis, therapy, and therapeutic targets is essential. Full article
(This article belongs to the Special Issue Advances in the Prognosis of Gastrointestinal Cancers)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop